Aerovate Therapeutics, Inc

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

MEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass

When even the sellside describes a biotech’s sole product as “an abject failure”, the company is clearly in trouble. Aerovate Therapeutics, Inc ’s value was shredded yesterday after it canned its pul

Last month, Merck & Co., Inc. ’s Winrevair (sotatercept) became the first disease-modifying therapy approved for pulmonary arterial hypertension (PAH) and expectations for the product are high, with